

## Załącznik nr 2. Charakterystyka pacjentów leczonych HDF

Tabela 1 Charakterystyka pacjentów leczonych HDF

	All patients	HD	All HDF	HDF 4.0–15.0L	HDF 15.1–20.0L	HDF >20.0L
Number of patients	8567	6555	2012	314	538	1010
Age (years)	65.8 ± 15.0	66.2 ± 14.9	64.8 ± 15.0	66.8 ± 15.4	65.2 ± 14.7	64.4 ± 15.1
Sex (% male)	61	60	66	56	65	69
Vintage (years)	2.5 (0.8–5.8)	2.3 (0.7–5.4)	3.2 (1.1–7.0)	3.3 (1.1–7.2)	2.9 (1.0–6.1)	3.4 (1.2–7.1)
Residual kidney function (%)	40	42	35	30	31	39
Vascular access (%)						
AV fistula	67	65	73	73	70	75
AV graft	6	6	6	6	9	5
Catheter	27	29	21	22	22	20
Achieved blood flow rate (mL/min)	319 ± 59	315 ± 58	333 ± 58	312 ± 54	327 ± 54	342 ± 59
Achieved treatment time (min)	239 ± 27	238 ± 26	243 ± 30	234 ± 30	240 ± 26	249 ± 31
Intradialytic weight loss (%)	2.5 ± 1.5	2.5 ± 1.5	2.5 ± 1.5	2.7 ± 1.6	2.6 ± 1.6	2.5 ± 1.5
BMI (kg/m <sup>2</sup> )	26.0 ± 5.4	26.0 ± 5.4	26.1 ± 5.6	25.4 ± 5.5	26.3 ± 5.5	26.1 ± 5.7
spKt/V	1.53 ± 0.33	1.50 ± 0.32	1.62 ± 0.34	1.49 ± 0.31	1.63 ± 0.32	1.66 ± 0.34
Albumin (g/dL)	3.73 ± 0.57	3.74 ± 0.57	3.68 ± 0.57	3.68 ± 0.48	3.72 ± 0.61	3.65 ± 0.57
nPCR (g/kg/day)	1.00 ± 0.25	1.00 ± 0.25	1.00 ± 0.23	1.00 ± 0.22	1.01 ± 0.24	1.00 ± 0.24
Phosphorus (mg/dL)	4.9 ± 1.6	5.0 ± 1.6	4.9 ± 1.6	5.0 ± 1.6	4.8 ± 1.7	4.8 ± 1.5
Hemoglobin (g/dL)	11.4 ± 1.4	11.3 ± 1.4	11.5 ± 1.4	11.5 ± 1.3	11.5 ± 1.4	11.5 ± 1.4
Ferritin (ng/mL)	380 (200–601)	377 (200–599)	392 (203–610)	376 (189–546)	399 (193–605)	394 (212–641)
CRP (mg/L)	6.0 (2.9–15.0)	6.0 (2.9–14.6)	5.4 (2.9–15.3)	7.4 (4.0–17.4)	5.5 (2.9–14.9)	5.0 (2.5–15.4)
WBC count (1000 cells/mm <sup>3</sup> )	7.1 ± 2.3	7.1 ± 2.3	6.9 ± 2.2	7.1 ± 2.1	6.8 ± 2.1	7.0 ± 2.3
Pre-dialysis SBP (mmHg)	137.9 ± 21.9	137.7 ± 21.7	138.4 ± 22.6	136.7 ± 24.3	137.5 ± 22.6	138.9 ± 22.0
Post-dialysis SBP (mmHg)	132.0 ± 22.6	132.1 ± 22.2	132.0 ± 23.9	130.7 ± 23.9	130.4 ± 23.3	132.8 ± 24.2
Transplant waiting list	12	11	13	12	12	13
Comorbid conditions (%)						
Coronary artery disease	35	35	36	35	35	38
Cancer (non-skin)	17	17	17	17	16	18
Other cardiovascular disease	31	31	31	31	29	33
Cerebrovascular disease	17	16	17	21	16	18
Congestive heart failure	19	20	16	15	15	17
Diabetes	36	36	37	36	36	38
Gastrointestinal bleeding	5	5	5	4	4	4
Hypertension	86	86	84	81	81	87
Lung disease	14	14	12	15	14	11
Neurologic disease	12	12	10	13	10	9
Psychiatric disorder	17	18	16	13	19	15
Peripheral vascular disease	30	30	32	32	31	33
Recurrent cellulitis, gangrene	9	9	10	10	11	10

Źródło: Locatelli, Karaboyas i Pisoni, 2018

Tabela 2 Charakterystyka pacjentów leczonych HDF

	Never Treated by HDF (n = 22,881)	Treated by HDF (n = 5,526)	P	Exclusively Treated by HDF (n = 2,254)	P
Age, y	70.6 [58.2-79.1]	71.4 [59.9-79.1]	0.001	73.3 [62.0-80.5]	<0.001
Male sex	14,322 (62.6)	3,465 (62.7)	0.9	1,392 (61.8)	0.4
Comorbid conditions					
Diabetes	9,185 (40.1)	2,608 (47.2)	<0.001	1,051 (46.6)	<0.001
Coronary heart disease	5,196 (22.7)	1,391 (25.2)	<0.001	559 (24.8)	0.03
Peripheral vascular disease	4,856 (21.2)	1,286 (23.3)	0.002	514 (22.8)	0.1
Stroke	2,416 (10.6)	654 (11.8)	0.01	264 (11.7)	0.1
Chronic respiratory disease	2,802 (12.2)	742 (13.4)	0.02	293 (13.0)	0.3
Arrhythmias	4,769 (20.8)	1,187 (21.5)	0.3	501 (22.2)	0.1
Heart failure	5,914 (25.8)	1,438 (26.0)	0.8	589 (26.1)	0.8
Myocardial infarction	2,443 (10.7)	644 (11.7)	0.05	257 (11.4)	0.3
Obesity: BMI $\geq 30$ kg/m <sup>2</sup>	5,110 (22.3)	1,511 (27.3)	<0.001	599 (26.6)	<0.001
Smoking					
Never smoker	13,351 (58.5)	3,065 (55.5)	<0.001	1,275 (56.5)	0.1
Former smoker	5,726 (25.0)	1,604 (29.0)	<0.001	640 (28.4)	0.002
Current smoker	3,805 (16.6)	859 (15.5)	0.08	341 (15.1)	0.1
Cirrhosis	449 (2.0)	127 (2.3)	0.1	58 (2.5)	0.1
Mobility					
Walk without help	18,579 (81.2)	4,452 (80.6)	0.3	1,746 (77.4)	<0.001
Need assistance	3,442 (15.0)	858 (15.5)	0.4	413 (18.3)	<0.001
Totally dependent for transfers	862 (3.8)	218 (3.9)	0.6	97 (4.3)	0.3
Primary kidney disease			<0.001		<0.001
Polycystic kidneys	1,522 (6.7)	225 (4.1)		73 (3.2)	
Hypertension	5,724 (25.0)	1,410 (25.5)		668 (29.6)	
Diabetic nephropathy	5,121 (22.4)	1,528 (27.7)		604 (26.8)	
Glomerulonephritis	2,483 (10.9)	571 (10.3)		203 (9.0)	
Pyelonephritis	965 (4.2)	192 (3.5)		76 (3.4)	
Vascular nephropathy	261 (1.1)	101 (1.8)		50 (2.2)	
Other and unknown	6,805 (29.7)	1,499 (27.1)		580 (25.7)	
Unplanned HD initiation	7,002 (30.6)	1,838 (33.2)	<0.001	787 (34.9)	<0.001
RRT initiation with catheter	11,458 (50.1)	2,919 (52.8)	<0.001	1,217 (54.0)	<0.001
RRT frequency $\geq 3 \times / \text{wk}$	21,415 (93.6)	5,123 (92.7)	0.02	2,032 (90.1)	<0.001
RRT session length $\geq 240$ min	17,465 (76.3)	4,120 (74.5)	0.006	1,583 (70.2)	<0.001
Facility type			<0.001		<0.001
In-center dialysis facility	20,385 (89.1)	5,238 (94.8)		2,181 (96.8)	
Satellite facility	754 (3.3)	141 (2.6)		21 (0.9)	
Self-dialysis	1,742 (7.6)	147 (2.7)		52 (2.3)	
Laboratory variables					
Albuminemia					
<25 g/L	2,243 (9.8)	512 (9.3)	0.3	203 (9.0)	0.3
25-<30 g/L	4,118 (18.0)	1,000 (18.1)	0.9	425 (18.8)	0.5
30-<35 g/L	6,677 (29.2)	1,674 (30.3)	0.2	687 (30.5)	0.3
$\geq 35$ g/L	9,845 (43.0)	2,342 (42.4)	0.5	940 (41.7)	0.3
eGFR					
<10 mL/min/1.73 m <sup>2</sup>	15,243 (66.6)	3,427 (62.0)	<0.001	1,296 (57.5)	<0.001
10-<15 mL/min/1.73 m <sup>2</sup>	5,284 (23.1)	1,453 (26.3)	<0.001	640 (28.3)	<0.001
$\geq 15$ mL/min/1.73 m <sup>2</sup>	2,356 (10.3)	647 (11.7)	0.008	320 (14.2)	<0.001
Hemoglobin					
<10 g/dL	9,596 (41.9)	2,289 (41.4)	0.5	866 (38.4)	0.006
10-<11 g/dL	5,323 (23.3)	1,295 (23.4)	0.8	547 (24.2)	0.3
11-<13 g/dL	6,651 (29.1)	1,645 (29.8)	0.3	712 (31.6)	0.03
$\geq 13$ g/dL	1,312 (5.7)	299 (5.4)	0.4	130 (5.8)	0.9

Źródło: Mercadal, 2015